Table 2. Characteristics of patients who failed to attain LDL-C goals stratified by follow-up treatment plans.

	Continue existing treatment (n = 270)	Add additional lifestyle modification (n = 38)	Intensify therapeutic dose (n = 38)	Switch medication (n = 63)	Switch medication after dose intensification (n = 11)
Age, years	65 ± 11	63 ± 11	68 ± 11	65 ± 11	63 ± 15
Women	89 (33)	16 (42)	11 (29)	26 (41)	2 (18)
Smoking	85 (31)	11 (29)	10 (26)	16 (25)	5 (45)
Family history of premature CHD	52 (19)	14 (37)	21 (55)	21 (33)	2 (18)
Hypertension	247 (91)	35 (92)	36 (95)	57 (90)	10 (91)
Diabetes	140 (52)	25 (66)	20 (53)	35 (56)	6 (55)
Multiple risk factors with 10-year risk for CHD > 20%	75 (28)	5 (13)	12 (32)	11 (17)	2 (18)
CHD	149 (55)	11 (29)	28 (74)	30 (48)	9 (82)
Carotid artery disease	0 (0)	0 (0)	3 (8)	5 (8)	1 (9)
LDL-C target < 70 mg/dL	207 (77)	23 (61)	34 (89)	49 (78)	10 (91)
Very high-risk category	197 (73)	23 (61)	34 (89)	51 (81)	10 (91)
Secondary prevention	164 (61)	30 (79)	34 (89)	40 (63)	10 (91)
Statin monotherapy	228 (84)	29 (76)	36 (95)	54 (86)	9 (82)
Metabolic syndrome element#
Abdominal obesity	192 (71)	29 (76)	29 (76)	47 (75)	5 (45)
Abnormal triglyceride	127 (48)	22 (58)	22 (58)	36 (57)	10 (91)
Low HDL-C	119 (45)	19 (50)	18 (47)	28 (44)	6 (55)
Abnormal BP	236 (87)	32 (84)	38 (100)	57 (90)	10 (91)
Impaired fasting glucose	179 (67)	30 (79)	32 (84)	57 (90)	7 (64)

* Data are in numbers (%) unless noted otherwise. ^# Abdominal obesity (waist > 90 cm in men or > 80 cm in women); abnormal triglyceride (≥ 150 mg/dL); low HDL-C (< 40 mg/dL in men or < 50 mg/dL in women); abnormal BP (≥ 130/≥ 85 mmHg); impaired fasting glucose (≥ 100 mg/dL).

BP, blood pressure; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.